

RSC Advances




This is an *Accepted Manuscript*, which has been through the Royal Society of Chemistry peer review process and has been accepted for publication.

Accepted Manuscripts are published online shortly after acceptance, before technical editing, formatting and proof reading. Using this free service, authors can make their results available to the community, in citable form, before we publish the edited article. This *Accepted Manuscript* will be replaced by the edited, formatted and paginated article as soon as this is available.

You can find more information about *Accepted Manuscripts* in the [Information for Authors](#).

Please note that technical editing may introduce minor changes to the text and/or graphics, which may alter content. The journal's standard [Terms & Conditions](#) and the [Ethical guidelines](#) still apply. In no event shall the Royal Society of Chemistry be held responsible for any errors or omissions in this *Accepted Manuscript* or any consequences arising from the use of any information it contains.

Use multi-particle delivery system to increase the bioavailability of tangeretin.



23 **Abstract**

24 The objective of this study was to evaluate the influence of dietary lipids on the
25 gastrointestinal fate of tangeretin-loaded zein nanoparticles. The zein delivery systems were
26 mixed with different amounts of oil-in-water emulsions to represent varying levels of digestible
27 fat in the diet, and then passed through a simulated gastrointestinal tract model. Tangeretin
28 bioaccessibility increased with increasing fat content due to enhanced solubilization within the
29 mixed micelles formed by lipid digestion products (fatty acids and monoacylglycerols) in the
30 intestinal fluids. Indeed, the tangeretin concentration in the micelle phase was about twelve times
31 higher in the presence of fat droplets than in their absence. The intestinal epithelium absorption
32 study indicated that tangeretin permeability across the model epithelium cells also increased with
33 increasing fat content. This study suggests that utilizing mixed colloidal systems consisting of
34 both lipid nanoparticles and protein nanoparticles may promote the bioavailability of
35 hydrophobic bioactive agents.

36

37 *Keywords:* nutraceuticals; tangeretin; delivery systems; nanoparticles; Caco-2 cells; permeability

38

39

40

41

42

43

44

45 1. Introduction

46 Tangeretin represents a class of polymethoxy flavonoids (PMFs) found almost exclusively
47 in citrus fruits, and particularly the peels of sweet and mandarin oranges ¹. PMFs have been
48 shown to exhibit a variety of potential benefits for human health, such as enhancing biochemical
49 events in mammalian cells ², reducing serum triacylglycerol, very low-density lipoprotein
50 (VLDL), and low-density lipoprotein (LDL) levels ³. PMFs can also inhibit the proliferation of
51 certain types of cancer cells, such as lung, colon and breast cancer cells ⁴. PMFs have also been
52 demonstrated to modulate the liver and heart function of hypercholesterolemic of rats ⁵.

53 However the oral bioavailability of tangeretin is currently limited due to its poor water
54 solubility, which is related to the presence of numerous methoxyl groups on the flavone
55 backbone ⁶. We have previously shown that zein nanoparticles and microparticles offer a suitable
56 means of encapsulating and delivering tangeretin ⁷. Colloidal particles can be formed from zein
57 using antisolvent precipitation due to its high solubility in alcohol solutions but low solubility in
58 water ⁸. The zein and active component are dissolved in an alcohol solution, which is then
59 injected into water, resulting in the spontaneous formation of zein particles containing the active
60 component. This method has been successfully used to encapsulate lipids, such as fish oil, flax
61 oil, and essential oils ⁹.

62 The purpose of the current study was to examine the impact of lipid nanoparticles on the
63 potential gastrointestinal fate of tangeretin-loaded zein nanoparticles. It is well known that co-
64 ingestion of digestible lipids can increase the oral bioavailability of lipophilic nutraceuticals and
65 pharmaceuticals by altering their bioaccessibility, absorption, or transformation within the
66 gastrointestinal tract ¹⁰. Lipids may enhance the bioavailability of lipophilic molecules through a
67 variety of mechanisms, including stimulating the secretion of digestive juices, increasing
68 gastrointestinal transit times, enhancing their solubility within intestinal fluids through mixed
69 micelle formation, increasing the permeability of the epithelium monolayer, controlling chemical
70 or biochemical transformation, or altering the absorption route (portal vein *versus* lymphatic
71 system). Recent study showed that the bioefficacy of tangeretin against cancer cells were
72 significantly improved when they were administered in emulsion ¹¹. Both in vitro and in vivo
73 studies indicated the bioavailability of tangeretin was increased when incorporated in to lipid
74 nanoemulsion ¹². We therefore hypothesized that mixing tangeretin-loaded zein nanoparticles

75 with digestible lipid nanoparticles would enhance the bioavailability of the lipophilic tangeretin
76 molecules. The influence of lipids on the potential biological fate of the tangeretin was studied
77 using a simulated gastrointestinal model that included mouth, stomach, and small intestine
78 phases, combined with a Caco-2 cell model to study permeability⁶.

79 An important aim of this study was to highlight the potential advantages of using
80 combination delivery systems containing a mixture of different types of colloidal particles (in
81 this case zein and lipid nanoparticles) rather than using single types of colloidal particle. This
82 information may be useful in the rational design of oral delivery systems for food and
83 pharmaceutical applications.

84 **2. Materials and Methods**

85 **2.1. Materials**

86 Tangeretin powder with a purity of 98.4% was obtained from Bepfarm Ltd. (Shanghai,
87 China). β -lactoglobulin (with a purity of 92.5%) was obtained from Daviso Foods International
88 (lot JE 002-8-415, Le Sueur, MN). Corn oil was obtained from a local supermarket. Zein (purity
89 92%, w/w), bile extract (porcine, B8613), porcine pancreas (Type II, triacylglycerol hydrolase
90 E.C. 3.1.1.1, PPL), Hank's balance salts (cat. no. H1387) and uranyl acetate were purchased from
91 Sigma-Aldrich (St Louis, MO). Pepsin (CAS: 9001-75-6), sodium chloride (NaCl), sodium
92 hydroxide (NaOH), calcium chloride (CaCl₂), hydrochloric acid (HCl), HPLC grade methanol,
93 tetrahydrofuran (THF), trifluoroacetic acid (TFA), acetonitrile (ACN) were obtained from Fisher
94 Scientific (Fairlawn, NJ, USA). Ammonium acetate was obtained from EMD Chemicals Inc.
95 (Gibbstwon, NJ, USA). Double distilled water was made from a water purification system
96 (Model D14031, Barnstead Nanopure water system, Dubuque, Iowa, USA). DMEM (Dulbecco's
97 Modification of Eagle's Medium) and non-essential amino acid was purchased from Mediatech
98 Inc., (Manassas, VA). HEPES was purchased from Acros Organics (Geel, Belgium).

99 **2.2. Preparation of tangeretin-loaded zein nanoparticles**

100 The tangeretin-loaded zein nanoparticles were made using an antisolvent precipitation
101 method described previously¹³, with some slight modifications. The particles were prepared by
102 injecting an organic phase into an aqueous phase. The organic phase consisted of zein and

103 tangeretin (25:1, w/w) dissolved in 90% ethanol solution, while the aqueous phase consisted of
104 β -lactoglobulin (3%, w/v) dissolved in PBS (10 mM, pH 7). The zein nanoparticles were formed
105 spontaneously when the organic phase was injected into the aqueous phase (1:3, v/v) dropwise
106 under constant stirring at 1000 rpm (Corning Stirrer PC-420, Corning Inc., USA). The ethanol in
107 the mixture was then evaporated with using a vacuum rotary evaporator (Rotavapor R110, Buchi
108 Crop., Switzerland). Then the sample was freeze dried (VirTis Genesis Lyophilizer, Virtis
109 genesis company inc., USA) and kept in a refrigerator prior to further use.

110 **2.3. Preparation of lipid nanoparticles**

111 β -lactoglobulin was dissolved in 10 mM phosphate buffer (3%, w/w) and stirred for at least
112 2 hours to ensure full hydration. A coarse emulsion was prepared by mixing 20% corn oil with
113 aqueous solution using a hand blender (M133/1280, Biospec Products, Inc., ESGC, Switzerland)
114 for 2 min. This coarse emulsion was then passed through a high pressure homogenizer
115 (Microfluidics M-110Y, Newton, MA) at 12,000 psi for 3 times.

116 **2.4. Particle size and ζ -potential measurement**

117 The particle size and ζ -potential of the nanoparticles were determined using a commercial
118 dynamic light scattering and micro-electrophoresis device (Nano-ZS, Malvern Instruments,
119 Worcestershire, UK). The samples were diluted 10 times in PBS buffer solutions (pH 7) at the
120 same pH as the samples being analyzed at room temperature before measurement. The particle
121 size is reported as the intensity-weighted ('Z-average') mean particle diameter, while the particle
122 charge is reported as the ζ -potential.

123 **2.5. Microstructure & visual observations**

124 The microstructure of the colloidal delivery systems was observed using an optical
125 microscope (Nikon Eclipse E400, Nikon Corp., Japan), and the resulting images were acquired
126 using digital image processing software (Micro Video Instruments Inc., Avon, MA). Selected
127 samples were also analyzed using transmission electron microscopy (JEOL JEM-2000FX, JEOL
128 USA, Inc., MA, USA). The general appearance of the colloidal systems and digesta after
129 different gastrointestinal stages were recorded by taking images using a digital camera
130 (Powershot SD1300IS, Canon).

131 2.6. Potential gastrointestinal fate of tangeretin-loaded zein nanoparticles

132 An *in vitro* digestion model was used to study the potential behavior of the delivery systems
133 under simulated gastrointestinal tract ¹⁴ conditions. Experiments were carried out at different
134 lipid contents by mixing the tangeretin-loaded zein nanoparticles with lipid nanoparticles to
135 simulate different diet compositions (*i.e.* high *versus* low fat diets).

136 Different delivery systems were prepared by mixing the freshly prepared tangeretin-loaded
137 zein nanoparticles and different amounts of stock nanoemulsion and phosphate buffer solution so
138 that they differed only in oil content (0%, 2%, and 4%). The samples were then passed through a
139 simulated GIT similar to that described earlier ¹⁵, but with some slight modifications.

140 *Mouth phase:* Oral conditions were mimicked by mixing the delivery systems with a
141 simulated saliva fluid (SSF), which was prepared from various salts and mucin as described
142 previously ¹⁶. Delivery systems were mixed with SSF at a 1:1 volume ratio, and then the
143 resulting mixture was adjusted to pH 6.8 and shaken continuously at 100 rev/min in an incubator
144 at 37 °C for 10 min (Innova Incubator Shaker, Model 4080, New Brunswick Scientific, New
145 Jersey, USA).

146 *Stomach phase:* Simulated gastric fluid was prepared by mixing 2 g of NaCl and 7 ml of
147 concentrated HCl and then making the volume up to 1 L using distilled water ¹⁶. Pepsin was then
148 dissolved in this mixture (0.32 %, w/v), the pH was adjusted to 1.2, and the sample from the
149 mouth phase was mixed with it at a 1:1 volume ration. The resulting mixture was then adjusted
150 to pH 2.5 and incubated at 100 rev/min and 37 °C for 2 hr.

151 *Small intestine:* Small intestine conditions were simulated using a pH-stat automatic titration
152 unit (Metrohm, USA Inc.). The sample collected from the stomach phase was placed in a
153 container placed in a 37 °C water bath. The pH was adjusted to pH 7.0. Bile salt (187.5 mg in 4
154 ml pH 7 PBS buffer solution) was then added, and the pH was adjusted back to 7.0. Calcium
155 chloride solution (110 mg dissolved in 1 ml double distilled water) was then added and again the
156 pH was adjusted to 7.0. Finally, freshly prepared pancreatin lipase (60 mg lipase in 2.5 ml pH 7.0
157 PBS) was added to the solution. At the same time, the automatic titration of pH-stat was started.
158 The free fatty acid released during digestion was calculated using the following equation ¹⁷:

$$159 \text{FFA}\% = 100 \times \left(\frac{V_{\text{NaOH}} \times m_{\text{NaOH}} \times M_{\text{lipid}}}{w_{\text{lipid}} \times 2} \right) \quad (1)$$

160 Here, V_{NaOH} is the volume of sodium hydroxide solution required to neutralize the free fatty
161 acids (and other sources of H^+) released during digestion; m_{NaOH} is the molar concentration of
162 sodium hydroxide solution, which is 0.25 M in this study; M_{lipid} is the molecular weight of corn
163 oil, which is 800 g/mol; w_{lipid} is the amount of oil in the reaction system.

164 2.7. Bioaccessibility determination

165 The samples obtained after *in vitro* digestion were collected and centrifuged (Centrifuge
166 5417R, Eppendorf co., Hamburg, Germany) (20200 g, 14000 rpm) at 4 °C for 40 min. The clear
167 micelle phase on the top layer of the samples was filtered through a 220 nm syringe filter (EMD
168 Millipore, Billerica, MA) and analyzed for the tangeretin content using the HPLC method
169 described before¹⁸. The bioaccessibility was then calculated using the following equation:

$$170 \quad \text{Bioaccessibility}(\%) = \frac{C_{\text{Micelle}}}{C_{\text{RawDigesta}}} \times 100\% \quad (2)$$

171 Here, C_{Micelle} is the concentration of tangeretin in the filtered micelle phase, and $C_{\text{Raw Digesta}}$ is the
172 concentration of tangeretin in the raw digesta.

173 2.8. Cytotoxicity measurement of micelle phase

174 Caco-2 cells were seeded in 96-well plates at a density of 20,000 cells/well in 200 μL
175 complete DMEM media (10% FBS, 1% antibiotic, 1% non-essential amino acid). After 24 h,
176 cells were treated with different concentrations of micelle phase diluted with serum complete
177 media. Tangeretin dissolved in DMSO was used as a control group and the final DMSO
178 concentration in the medium was less than 1%. After incubation for 24 h, cells were analyzed
179 using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. Media in
180 each well was replaced by 100 μL freshly prepared MTT solution (0.5 mg/mL dissolved in
181 DMEM media). After 2 h incubation at 37 °C, MTT solution was dumped and the reduced
182 formazan dye was solubilized by adding 100 μL of DMSO to each well. After gentle mixing, the
183 absorbance was monitored at 570 nm using a plate reader (TECAN, Phenix Research Products,
184 Candler, NC, USA)¹⁹.

185 2.9. Tangeretin permeability determination using Caco-2 monolayers

186 Caco-2 cell monolayer maintenance and permeability determination was conducted as
187 described before²⁰. Caco-2 cells were seeded on transwell permeable supports containing 0.4 μm
188 polycarbonate membranes (Corning Incorporated, Corning, NY) at a seeding density of 2.6×10^5
189 cells / cm^2 . The medium was changed 16 h after seeding. The media in the apical and basolateral
190 compartments were changed every other day. This process was maintained for about 21 days
191 until the transendothelial electrical resistance of the filter was about $260 \Omega \text{ cm}^2$.

192 The micelle phases were collected after *in vitro* digestion and filtered through a 220 nm
193 membrane. They were then diluted with Hank's Balanced Salt (HBSS, pH 7.4) to obtain
194 tangeretin concentrations suitable for permeability determinations. Tangeretin dissolved in
195 DMSO was used as a control group. All the solutions used in this experiment were pre-warmed
196 in a 37 °C water bath. The Caco-2 monolayer transwell was incubated with HBSS for 30 min
197 before the experiment. Then both the apical and basolateral compartments were rinsed twice with
198 HBSS). An aliquot (1.5 ml) of each sample was added to the apical compartment and 2.5 ml pre-
199 warmed HBSS was added to the basolateral compartment. Then, this plate was placed in an
200 incubator. Every 30 min, 200 μL of solution was withdrawn from the apical compartment
201 without adding new sample and 100 μL of sample was taken from the basolateral compartment
202 and replaced by same amount of pre-warmed HBSS. The whole experiment duration was 2 hours.
203 The transendothelial electrical resistance were monitored every time before and after the
204 experiment and before each sampling time. The concentration of tangeretin in each sample were
205 analyzed using HPLC method. The apparent permeability coefficient (cm s^{-1}) was calculated
206 with the following equation:

$$207 \quad P_{app} = (dQ/dt)(1/(AC_0)) \quad (3)$$

208 dQ/dt is the steady-state flux ($\mu\text{mol s}^{-1}$), A is the surface of the filter (4.67 cm^2), C_0 is the
209 concentration of tangeretin added to apical compartment of each well (μM).

210 2.10. Data analysis

211 All data in this study are expressed as mean \pm SD. Student's t-test was used to determine the
212 significance of difference between two groups. One way ANOVA was used to analyze the
213 significance of difference for more than three groups. 5% significance level was used for all tests.

214 **3. Results and Discussion**

215 **3.1. Characterization of delivery systems**

216 In this study, mixed delivery systems were prepared that contained a combination of
217 tangeretin-loaded zein nanoparticles and digestible lipid nanoparticles. Knowledge of the initial
218 characteristics of these nanoparticles is important to understand their subsequent behavior in the
219 simulated GIT. We therefore measured the size, charge, and morphology of the particles using
220 light scattering, electrophoresis, and microscopy. The mean particle diameters of the freshly
221 prepared nanoemulsions, tangeretin-loaded zein nanoparticles, and their mixture were 197, 248,
222 and 215 nm respectively (**Fig.1**). The ζ -potentials of the initial lipid nanoparticles (-29 mV),
223 tangeretin-loaded zein nanoparticles (-25 mV) and mixed system (-52 mV) were all highly
224 negative. The transmission electron microscopy (TEM) measurements suggested that the zein
225 nanoparticles (smooth surfaces) and lipid nanoparticles (crinkly surfaces) existed separately in
226 the mixture (**Fig. 1**), which can be attributed to the strong electrostatic repulsion between them.
227 We confirmed the nature of the different kinds of nanoparticles in the mixed systems by taking
228 TEM images of samples containing only lipid nanoparticles which had crinkly surfaces and only
229 zein nanoparticles which had smooth surfaces (data not shown). The crinkly appearance of the
230 lipid nanoparticles is probably due to crystallization of the uranyl acetate dye on their surfaces
231 during sample preparation for electron microscopy. Optical microscopy images of the mixed
232 delivery systems confirmed that they had good stability to aggregation, with no evidence of large
233 particles in the system (**Fig. 2a**). The colloidal delivery systems all had good stability to
234 gravitational separation (creaming or sedimentation), as demonstrated by the fact that no phase
235 separation was observed after 24 hours incubation, which can be attributed to their small initial
236 particle size and stability to aggregation.

237 **3.2. Gastrointestinal fate of colloidal delivery systems**

238 Colloidal delivery systems encounter a series of physicochemical and physiological
239 environments as they pass through the various stages of the human GIT, such as changes in pH,
240 ionic strength, agitation, enzyme activities, and surface active agents²¹. We therefore measured
241 changes in the properties of mixed colloidal delivery systems (containing 2% fat) as they passed
242 through the simulated mouth, stomach, and small intestine phases of the GIT model.

243 *Mouth:* The mean diameter of the particles in the system increased from around 215 to 424
244 nm after incubation in the simulated saliva fluids (**Fig. 3a**), which suggests that some particle
245 aggregation occurred. This observation was supported by the optical microscopy images, which
246 clearly showed evidence of extensive particle aggregation (**Fig. 2b**). The origin of this effect can
247 be attributed to particle flocculation induced by the presence of mucin in the artificial saliva.
248 Mucin is a large glycoprotein that can promote particle aggregation under oral conditions
249 through both bridging and depletion mechanisms²². The magnitude of the negative charge on
250 the particles decreased when they moved from the initial to the mouth phases (**Fig. 3b**), which
251 can be attributed to electrostatic screening effects by salts in the simulated saliva, as well as to
252 possible adsorption of mucin molecules to the lipid droplet surfaces.

253 *Stomach:* There was a large increase in the mean particle diameter measured by light
254 scattering (**Fig 3a**) and evidence of extensive particle aggregation in the optical microscopy
255 images (**Fig 2c**) when the samples moved from the mouth to the stomach phases. A number of
256 different physicochemical phenomena may contribute to the instability of the nanoparticles
257 within the gastric environment. First, both the zein and lipid nanoparticles used in this study
258 were coated with a globular protein (β -lactoglobulin) that has an isoelectric point around pH 5.
259 Consequently, the nanoparticles will have passed through a point of zero charge when they
260 moved from the simulated mouth (pH 7) to the simulated gastric (pH 2) fluids, which may have
261 promoted irreversible aggregation due to a reduction in electrostatic repulsion. Second, anionic
262 mucin molecules from the saliva may have caused bridging flocculation of the cationic protein-
263 coated nanoparticles in the stomach. Third, the relatively high ionic strength of the gastric fluids
264 may have reduced any electrostatic repulsion between the nanoparticles leading to aggregation.
265 Fourth, hydrolysis of the β -lactoglobulin coating around the nanoparticles by digestive enzymes
266 (pepsin) may have reduced their aggregation stability. The electrical charge on the nanoparticles
267 in the stomach was close to zero (**Fig. 3b**). One might expect nanoparticles coated by β -
268 lactoglobulin to be strongly positively charged at pH 2 because this is well below their isoelectric
269 point. The fact that the charge was near zero may have been because anionic mucin adsorbed to
270 the droplet surfaces, thereby neutralizing some of the positive charge from the proteins. In
271 addition, some of the surface proteins may have been digested by the pepsin, which would have
272 altered the surface charge. The droplets in the emulsion were highly unstable to gravitational
273 separation (**Fig. 3a**) under gastric conditions, which can be attributed to the relatively large

274 particle size caused by droplet aggregation. Interestingly, we did not observe a sediment layer in
275 these systems suggesting that the zein nanoparticles associated with the lipid nanoparticles and
276 the overall density of the flocs formed was less than that of water.

277 *Small Intestine:* The mean particle diameter remained relatively large after incubation in the
278 small intestinal fluids (**Fig. 3a**), but the large aggregates formed within the gastric fluids
279 appeared to have largely dissociated (**Fig 2d**). In the presence of pancreatin, the triacylglycerol
280 molecules in the lipid droplets will be converted to a monoacylglycerol²³ and two free fatty
281 acids (FFAs) by pancreatic lipase. These MAG and FFAs will combine with phospholipids and
282 bile salts to form mixed micelles (micelles and vesicles) that can solubilize lipophilic compounds,
283 and then carry them through the mucous layer to the small intestine cell surfaces^{10a}. The
284 pancreatic lipase used in this study was a crude extract that also has protease activity.
285 Consequently, the β -lactoglobulin and zein in the protein nanoparticles would have been fully or
286 partially hydrolyzed, thereby releasing the tangeretin in the intestinal fluids. As a result, the
287 digesta is likely to contain a complex mixture of different types of colloidal particles, including
288 undigested lipid particles, undigested protein particles, micelles, vesicles, and insoluble matter.
289 The high negative charge on the particles in these samples can therefore be attributed to the
290 anionic nature of the free fatty acids, bile salts, phospholipids, and proteins at neutral pH
291 conditions (**Fig. 3b**).

292 3.3. Digestibility of colloidal delivery systems

293 In this section, we used the pH-stat method to measure the digestion of the various colloidal
294 delivery systems. As mentioned earlier, the crude pancreatic lipase extract used in this study has
295 both lipase and protease activity, and therefore we would expect both the proteins and lipids to
296 be digested. The amount of alkaline solution required to maintain the solution at pH 7.0
297 throughout the digestion period was measured (**Fig. 4a**), and then this information was used to
298 calculate the percentage of free fatty acids (FFA) released from the samples containing lipid
299 nanoparticles (**Fig. 4b**). Prior to calculating the FFAs for these samples, the volume of alkaline
300 solution titrated into the lipid-free solutions was subtracted to take into account changes in pH
301 induced by protein digestion.

302 The volume of alkaline solution titrated into the samples increased rapidly during the first
303 few minutes of digestion, and then increased more gradually at longer digestion times (**Fig. 4a**).

304 The fact that an appreciable increase in volume was observed for the system containing no lipids
305 can be attributed to the hydrolysis of proteins (β -lactoglobulin and/or zein). For both systems
306 containing lipid nanoparticles, there was a rapid initial increase in FFAs released during the first
307 10 minutes, and then a relatively constant value was reached at longer times (**Fig. 4b**). These
308 results suggest that the lipid phases were fully digested within the small intestine stage, thereby
309 leading to the formation of free fatty acids and monoacylglycerols that could form mixed
310 micelles to solubilize the tangeretin. The fact that the delivery system initially containing 4% oil
311 had twice as much digestible lipid as the one containing 2% oil would be expected to lead to
312 more mixed micelles.

313 **3.4. Tangeretin bioaccessibility**

314 The amount of a lipophilic bioactive component solubilized within the mixed micelle phase
315 is normally taken as a measure of its bioaccessibility²⁴. We therefore analyzed the amount of
316 tangeretin in the mixed micelle phase obtained by centrifuging the digested sample collected at
317 the end of the GIT model. Normally after centrifugation, the digested sample has three layers: a
318 creamy layer at the top containing any undigested lipid; a clear layer at the middle containing the
319 mixed micelles; and a pellet at the bottom containing dense insoluble materials, such as calcium
320 soaps, undigested proteins, and precipitated compounds^{10a}. In our study, all of the fat in the
321 delivery systems was fully digested (**Fig. 4b**), and so only two layers were observed: the mixed
322 micelle phase and the pellet.

323 The bioaccessibility of the tangeretin increased as the concentration of co-ingested lipid
324 phase increased (**Fig. 5**), being around 15, 26, and 37 % for delivery systems initially containing
325 0, 2 and 4% oil. As mentioned earlier, this effect can be attributed to the increased level of mixed
326 micelles available to solubilize any lipophilic tangeretin molecules released from the digested
327 zein nanoparticles²⁵. At the highest fat content used in this study, the tangeretin concentration in
328 the micelle phase was determined to be $12.4 \pm 1.8 \mu\text{M}$, while the saturation concentration of
329 tangeretin in pure water is around $0.93 \pm 0.02 \mu\text{M}$, which clearly shows that the digested lipids
330 were able to greatly increase tangeretin solubilization in the aqueous intestinal fluids.

331 Further information about the properties of the mixed micelle phase was obtained by
332 analyzing the particle size using dynamic light scattering. The mean diameters of the particles in
333 the micelle phase for delivery systems initially containing 0, 2 or 4% oil were 61.5, 69.1 and

334 112.5 nm, respectively. In the absence of fat, these particles may have been micelles formed by
335 the bile salts and phospholipids in the simulated small intestinal fluids. In addition, there may
336 have been other forms of particles present in this phase, including protein nanoparticles that were
337 not fully digested. In the presence of fat, the increase in particle size may have been due to the
338 presence of mixed micelles consisting of bile salts, phospholipids, free fatty acids, and
339 monoacylglycerols. The mixed micelle phase resulting from lipid digestion typically contains a
340 combination of small micelles and large vesicle structures²⁶. These mixed micelles are able to
341 transfer the lipophilic bioactive components across the mucous layer so that they can be absorbed
342 by epithelium cells^{10a, 27}.

343 **3.5. Cytotoxicity of tangeretin on Caco-2 cells**

344 When performing cell permeability studies it is important to ensure that the material being
345 tested does not appreciably alter cell viability. An MTT assay was therefore carried out to
346 establish the potential toxicity of the mixed micelle phases collected from the simulated GIT on
347 the Caco-2 cell monolayers. Tangeretin dissolved within DMSO did not significantly decrease
348 cell viability over a relatively wide concentration range (**Fig. 6**), *e.g.*, at 0.1 μM almost all the
349 cells were alive, and even at 20 μM the cell viability was still around 80%. Prior to analysis the
350 mixed micelle phases were diluted with buffer solution to obtain a range of tangeretin
351 concentrations. Consequently, both the tangeretin and mixed micelle concentrations in these
352 samples varied. Our results suggest that the mixed micelles had an appreciable impact on cell
353 viability, since when compared at the same tangeretin concentrations they caused more decrease
354 in cell viability than the control (**Fig. 6**). For example, cell viability was close to 100% at 0.1 μM
355 tangeretin (0.1% v/v mixed micelle phase), but only 20% at 20 μM tangeretin (20% v/v mixed
356 micelle phase). This effect may be caused by increased levels of bile salts in the system, since it
357 has previously been reported that these surface active lipids promote cell death by binding to the
358 mitochondrial membrane, which causes loss of cytochrome activity and mitochondrial
359 membrane potential²⁸. For this reason, we used a tangeretin concentration of 5 μM in our
360 permeability studies to ensure that the mixed micelles did not promote a significant decline in
361 Caco-2 cell viability.

362 3.6. Permeability of digested tangeretin micelle on Caco-2 cell monolayer

363 Tangeretin concentration used for this study was 5 μM based on our MTT result. As shown
364 in **Fig.7a**, Caco-2 cell monolayer integrity was well maintained during the two hour treatment.
365 During The permeability of the Caco-2 cells increased with increasing fat content in the mixed
366 colloidal dispersions, as demonstrated by the faster rate of tangeretin loss from the apical side of
367 the cells for the samples initially containing 4% oil (**Fig. 7b**). In addition, the calculated
368 apparent permeability coefficients (P_{app}) of the tangeretin were $(18.1 \pm 4.5) \times 10^{-6}$, $(17.1 \pm 1.8) \times$
369 10^{-6} , $(19.3 \pm 2.0) \times 10^{-6}$, and $(26.8 \pm 1.8) \times 10^{-6}$ cm/s for the control group, micelles from 0% oil,
370 micelles from 2% oil, and micelles from 4% oil, respectively (**Table 1**). It has been reported that
371 a substance has a high permeability when its P_{app} is greater than 10×10^{-6} cm/s⁶, and so all the
372 samples analyzed in this study had high permeability. Nevertheless, the permeability of
373 tangeretin did increase with increasing oil content in the initial delivery system, which can be
374 partly attributed to the ability of the mixed micelles formed by lipid digestion products to
375 increase the intestinal solubility of tangeretin^{10a, 10c}. In addition, free fatty acids and emulsifiers
376 are known to enhance intestinal permeability by increasing the dimensions of the tight junctions
377 between epithelium cells²⁹.

378 4. Conclusions

379 This study shows that the bioavailability of tangeretin encapsulated within zein
380 nanoparticles can be increased by mixing them with lipid nanoparticles. This result supports the
381 notion that mixed delivery systems containing combinations of different kinds of nanoparticles
382 may have advantages over single-nanoparticle systems. One kind of nanoparticle may be
383 designed to encapsulate and protect the bioactive agent in a product during storage, whereas the
384 other kind of nanoparticle is designed to increase its bioavailability within the gastrointestinal
385 tract.

386 Light scattering and microscopy measurements showed that mixed colloidal delivery
387 systems could be successfully prepared containing a combination of tangeretin-loaded zein
388 nanoparticles and lipid nanoparticles. These systems appeared to be stable to aggregation and
389 gravitational separation due to their high particle charge and small particle size. When these
390 mixed colloidal delivery systems were passed through a simulated GIT the protein nanoparticles

391 are digested by proteases thereby releasing the tangeretin molecules, whereas the lipid
392 nanoparticles are digested by pancreatic lipases thereby forming mixed micelles. In the absence
393 of lipid digestion products, some of the tangeretin molecules would have been solubilized in
394 simple micelles formed by bile salts and phospholipids, whereas the rest may have formed
395 crystals that remained in the insoluble matter. Conversely, in the presence of lipid digestion
396 products (free fatty acids and monoacylglycerols) the solubilization capacity of the small
397 intestinal fluids for the tangeretin molecules is increased. The absorption of the tangeretin by
398 Caco-2 monolayers also increased in the presence of lipid nanoparticles, which was attributed to
399 a higher level of tangeretin in the micelle phase, and a possible increase in cell permeability.
400 The results of this study have important implications for the design and fabrication of colloidal
401 delivery systems to increase the bioavailability of hydrophobic nutraceuticals and
402 pharmaceuticals.

403 **Acknowledgements**

404 This material was partly based upon work supported by the Cooperative State Research,
405 Extension, Education Service, USDA, Massachusetts Agricultural Experiment Station (Project
406 No. 831) and USDA, NRI Grants (2011-03539, 2013-03795, 2011-67021, and 2014-67021) and
407 an NSF of China grant (31428017). This project was also partly funded by the Deanship of
408 Scientific Research (DSR), King Abdulaziz University, Jeddah, under grant numbers 330-130-
409 1435-DSR, 299-130-1435-DSR, 87-130-35-HiCi. The authors, therefore, acknowledge with
410 thanks DSR technical and financial support.

411

412 **References**

- 413 1. Xiao, H.; Yang, C. S.; Li, S.; Jin, H.; Ho, C.-T.; Patel, T., Monodemethylated polymethoxyflavones from
414 sweet orange (*Citrus sinensis*) peel Inhibit growth of human lung cancer cells by apoptosis. *Molecular*
415 *Nutrition & Food Research* **2009**, *53* (3), 398-406.
- 416 2. Singh, S. P.; Wahajuddin; Tewari, D.; Patel, K.; Jain, G. K., Permeability determination and
417 pharmacokinetic study of nobiletin in rat plasma and brain by validated high-performance liquid
418 chromatography method. *Fitoterapia* **2011**, *82* (8), 1206-1214.

- 419 3. Kurowska, E. M.; Manthey, J. A., Hypolipidemic Effects and Absorption of Citrus Polymethoxylated
420 Flavones in Hamsters with Diet-Induced Hypercholesterolemia. *J Agr Food Chem* **2004**, *52* (10), 2879-
421 2886.
- 422 4. (a) Qiu, P.; Dong, P.; Guan, H.; Li, S.; Ho, C.-T.; Pan, M.-H.; McClements, D. J.; Xiao, H., Inhibitory
423 effects of 5-hydroxy polymethoxyflavones on colon cancer cells. *Molecular Nutrition & Food Research*
424 **2010**, *54* (S2), S244-S252; (b) Pan, M.-H.; Lai, Y.-S.; Lai, C.-S.; Wang, Y.-J.; Li, S.; Lo, C.-Y.; Dushenkov, S.;
425 Ho, C.-T., 5-Hydroxy-3,6,7,8,3',4'-hexamethoxyflavone Induces Apoptosis through Reactive Oxygen
426 Species Production, Growth Arrest and DNA Damage-Inducible Gene 153 Expression, and Caspase
427 Activation in Human Leukemia Cells. *J Agr Food Chem* **2007**, *55* (13), 5081-5091; (c) Sergeev, I. N.; Li, S.;
428 Colby, J.; Ho, C.-T.; Dushenkov, S., Polymethoxylated flavones induce Ca²⁺-mediated apoptosis in breast
429 cancer cells. *Life Sciences* **2006**, *80* (3), 245-253.
- 430 5. Green, C. O.; Wheatley, A. O.; McGrowder, D. A.; Dilworth, L. L.; Asemota, H. N., Citrus peel
431 polymethoxylated flavones extract modulates liver and heart function parameters in diet induced
432 hypercholesterolemic rats. *Food and Chemical Toxicology* **2013**, *51* (0), 306-309.
- 433 6. Li, S.; Pan, M.-H.; Lo, C.-Y.; Tan, D.; Wang, Y.; Shahidi, F.; Ho, C.-T., Chemistry and health effects of
434 polymethoxyflavones and hydroxylated polymethoxyflavones. *Journal of Functional Foods* **2009**, *1* (1), 2-
435 12.
- 436 7. Chen, J.; Zheng, J.; McClements, D. J.; Xiao, H., Tangeretin-loaded protein nanoparticles fabricated
437 from zein/ β -lactoglobulin: Preparation, characterization, and functional performance. *Food Chemistry*
438 **2014**, *158* (0), 466-472.
- 439 8. Joye, I. J.; McClements, D. J., Production of nanoparticles by anti-solvent precipitation for use in
440 food systems. *Trends in Food Science & Technology* **2013**, *34* (2), 109-123.
- 441 9. (a) Quispe-Condori, S.; Saldaña, M. D. A.; Temelli, F., Microencapsulation of flax oil with zein using
442 spray and freeze drying. *LWT - Food Science and Technology* **2011**, *44* (9), 1880-1887; (b) Wu, Y.; Luo, Y.;
443 Wang, Q., Antioxidant and antimicrobial properties of essential oils encapsulated in zein nanoparticles
444 prepared by liquid-liquid dispersion method. *LWT - Food Science and Technology* **2012**, *48* (2), 283-290;
445 (c) Zhong, Q.; Jin, M., Zein nanoparticles produced by liquid-liquid dispersion. *Food Hydrocolloids* **2009**,
446 *23* (8), 2380-2387.
- 447 10. (a) Porter, C. J.; Trevaskis, N. L.; Charman, W. N., Lipids and lipid-based formulations: optimizing the
448 oral delivery of lipophilic drugs. *Nat Rev Drug Discov* **2007**, *6* (3), 231-48; (b) McClements, D. J.; Xiao, H.,
449 Excipient foods: designing food matrices that improve the oral bioavailability of pharmaceuticals and
450 nutraceuticals. *Food & Function* **2014**, *5* (7), 1320-1333; (c) McClements, D. J., Utilizing food effects to
451 overcome challenges in delivery of lipophilic bioactives: structural design of medical and functional
452 foods. *Expert Opinion on Drug Delivery* **2013**, *10* (12), 1621-1632.
- 453 11. Ting, Y.; Chiou, Y.-S.; Pan, M.-H.; Ho, C.-T.; Huang, Q., In vitro and in vivo anti-cancer activity of
454 tangeretin against colorectal cancer was enhanced by emulsion-based delivery system. *Journal of*
455 *Functional Foods* **2015**, *15*, 264-273.
- 456 12. Ting, Y.; Jiang, Y.; Lan, Y.; Xia, C.; Lin, Z.; Rogers, M. A.; Huang, Q., Viscoelastic Emulsion Improved
457 the Bioaccessibility and Oral Bioavailability of Crystalline Compound: A Mechanistic Study Using in Vitro
458 and in Vivo Models. *Molecular Pharmaceutics* **2015**, *12* (7), 2229-2236.
- 459 13. Parris, N.; Cooke Peter, H.; Moreau Robert, A.; Hicks Kevin, B., Encapsulation of Essential Oils in Zein
460 Nanospherical Particles. In *New Delivery Systems for Controlled Drug Release from Naturally Occurring*
461 *Materials*, American Chemical Society: 2008; Vol. 992, pp 175-192.

- 462 14. Christensen, J. Ø.; Schultz, K.; Mollgaard, B.; Kristensen, H. G.; Mullertz, A., Solubilisation of poorly
463 water-soluble drugs during in vitro lipolysis of medium- and long-chain triacylglycerols. *European Journal*
464 *of Pharmaceutical Sciences* **2004**, *23* (3), 287-296.
- 465 15. Li, Y.; McClements, D. J., Controlling lipid digestion by encapsulation of protein-stabilized lipid
466 droplets within alginate–chitosan complex coacervates. *Food Hydrocolloids* **2011**, *25* (5), 1025-1033.
- 467 16. Sarkar, A.; Goh, K. K. T.; Singh, H., Colloidal stability and interactions of milk-protein-stabilized
468 emulsions in an artificial saliva. *Food Hydrocolloids* **2009**, *23* (5), 1270-1278.
- 469 17. Li, Y.; McClements, D. J., New Mathematical Model for Interpreting pH-Stat Digestion Profiles:
470 Impact of Lipid Droplet Characteristics on in Vitro Digestibility. *J Agr Food Chem* **2010**, *58* (13), 8085-
471 8092.
- 472 18. Dong, P.; Qiu, P.; Zhu, Y.; Li, S.; Ho, C.-T.; McClements, D. J.; Xiao, H., Simultaneous determination of
473 four 5-hydroxy polymethoxyflavones by reversed-phase high performance liquid chromatography with
474 electrochemical detection. *Journal of Chromatography A* **2010**, *1217* (5), 642-647.
- 475 19. Horie, M.; Kato, H.; Fujita, K.; Endoh, S.; Iwahashi, H., In Vitro Evaluation of Cellular Response
476 Induced by Manufactured Nanoparticles. *Chemical Research in Toxicology* **2011**, *25* (3), 605-619.
- 477 20. Ina, H.; Eva, G. E. R.; Per, A., Determination of drug permeability and prediction of drug absorption
478 in Caco-2 monolayers. *Nature Protocols* **2007**, *2* (9), 2111-2119.
- 479 21. McClements, D. J., Crystals and crystallization in oil-in-water emulsions: Implications for emulsion-
480 based delivery systems. *Advances in Colloid and Interface Science* **2012**, *174*, 1-30.
- 481 22. Vingerhoeds, M. H.; Blijdenstein, T. B. J.; Zoet, F. D.; van Aken, G. A., Emulsion flocculation induced
482 by saliva and mucin. *Food Hydrocolloids* **2005**, *19* (5), 915-922.
- 483 23. Cuyckens, F.; Claeys, M., Mass spectrometry in the structural analysis of flavonoids. *Journal of Mass*
484 *Spectrometry* **2004**, *39* (1), 1-15.
- 485 24. McClements, D. J.; Li, F.; Xiao, H., The Nutraceutical Bioavailability Classification Scheme: Classifying
486 Nutraceuticals According to Factors Limiting their Oral Bioavailability. *Annual review of food science and*
487 *technology* **2015**, *6*, 299-327.
- 488 25. Thakkar, S. K.; Maziya-Dixon, B.; Dixon, A. G.; Failla, M. L., Beta-carotene micellarization during in
489 vitro digestion and uptake by Caco-2 cells is directly proportional to beta-carotene content in different
490 genotypes of cassava. *J Nutr* **2007**, *137* (10), 2229-33.
- 491 26. Phan, S.; Salentinig, S.; Gilbert, E.; Darwish, T. A.; Hawley, A.; Nixon-Luke, R.; Bryant, G.; Boyd, B. J.,
492 Disposition and crystallization of saturated fatty acid in mixed micelles of relevance to lipid digestion.
493 *Journal of Colloid and Interface Science* **2015**, *449*, 160-166.
- 494 27. Lafitte, G.; Thuresson, K.; Soderman, O., Diffusion of nutrients molecules and model drug carriers
495 through mucin layer investigated by magnetic resonance imaging with chemical shift resolution. *Journal*
496 *of Pharmaceutical Sciences* **2007**, *96* (2), 258-263.
- 497 28. Schulz, S.; Schmitt, S.; Wimmer, R.; Aichler, M.; Eisenhofer, S.; Lichtmanegger, J.; Eberhagen, C.;
498 Artmann, R.; Tookos, F.; Walch, A.; Krappmann, D.; Brenner, C.; Rust, C.; Zischka, H., Progressive stages
499 of mitochondrial destruction caused by cell toxic bile salts. *Biochimica et Biophysica Acta (BBA) -*
500 *Biomembranes* **2013**, *1828* (9), 2121-2133.

501 29. Ulluwishewa, D.; Anderson, R. C.; McNabb, W. C.; Moughan, P. J.; Wells, J. M.; Roy, N. C.,
502 Regulation of tight junction permeability by intestinal bacteria and dietary components. *J Nutr* **2011**, *141*
503 (5), 769-76.

504

505




Figure 1. Particle size distribution of fat droplets, protein nanoparticles, and the mixed system.

The inset shows a transmission electron microscopy image of the mixed system.




Figure 2. Microscopic image of initial delivery system (a) and delivery system after digestion in (b) mouth, (c) stomach, (d) small intestine.




Figure 3a. Mean particle diameters and appearances of mixed systems initially containing protein nanoparticles and lipid nanoparticles (2% oil) after passage through various stages of a simulated gastrointestinal tract (GIT). The inset shows the appearance of the system at different digestion stages (Means with different letters are significantly different, $p < 0.05$).




Figure 3b. Mean particle charges of mixed systems initially containing protein nanoparticles and lipid nanoparticles (2% oil) after passage through various stages of a simulated gastrointestinal tract (GIT). The inset shows the appearance of the system at different digestion stages. (Means with different letters are significantly different, $p < 0.05$).




Figure 4a. pH-Stat titration curves carried out under simulated small intestinal conditions for mixed colloidal delivery systems containing tangeretin-loaded zein nanoparticles and different concentrations of lipid nanoparticles (0 to 4% oil).




Figure 4b. Calculated free fatty acids released under simulated small intestinal conditions for mixed colloidal delivery systems containing tangeretin-loaded zein nanoparticles and different initial concentrations of lipid nanoparticles (2 or 4% oil).




Figure 5. Influence of initial oil content on tangeretin bioaccessibility in mixed colloidal delivery systems containing tangeretin-loaded zein nanoparticles and lipid nanoparticles (Means with different letters are significantly different, $p < 0.05$).




Figure 6. Influence of tangeretin dissolved in DMSO or mixed micelles on Caco-2 cell viability. Cells were seeded at 20,000 cells/well on a 96 well plate 24 hours before treatment. The samples were diluted using serum complete media to obtain a range of tangeretin concentrations (*, $p < 0.05$).




Figure 7a. TEER percentage of each sample at different time.




Figure 7b: Tangeretin concentration in the apical compartment of Caco-2 transwell cells at different times for different delivery systems. *Control*: tangeretin dissolved in HBSS; 0% oil: digested phase from tangeretin nanoparticles with no oil; 2%: digested phase from tangeretin nanoparticles mixed with 2% oil; 4%: digested phase from tangeretin nanoparticles mixed with 4% oil. The oil was delivered as lipid nanoparticles.

Table 1. Caco-2 monolayer permeability of digested phases from delivery systems initially containing tangeretin nanoparticles and different oil contents (delivered in the form of lipid nanoparticles). The control consisted of tangeretin dissolved in DMSO.

Delivery System	P_{app} ($\times 10^{-6}$ cm/s)
Control	18.1 ± 4.5^a
0% oil	17.1 ± 1.8^a
2% oil	19.3 ± 2.0^a
4% oil	26.8 ± 1.8^b

*Means with different letters are significantly different, $p < 0.05$.